home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.78 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

2 Biotech Stocks to Buy Hand Over Fist in March ↗

March 08, 2024

These stocks are worth buying in most months of the year.

Via The Motley Fool

3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success ↗

March 06, 2024

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

March 05, 2024

EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 02, 2024

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

Via The Motley Fool

Topics Stocks

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 27, 2024

From Exelixis, Inc.

Via Business Wire

2 Stocks Under $30 to Buy and Hold ↗

February 19, 2024

You don't need to be a millionaire to get started. Investing on a budget can work, too.

Via The Motley Fool

Recap: Exelixis Q4 Earnings ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Preview For Exelixis ↗

February 05, 2024

Via Benzinga

Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗

February 23, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. ↗

February 05, 2024

NASDAQ:EXEL, a growth stock which is not overvalued.

Via Chartmill

Breaking Down Exelixis: 7 Analysts Share Their Views ↗

January 30, 2024

Via Benzinga

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

From FN Media Group LLC

Via GlobeNewswire

The 3 Best Biotech Stocks to Buy in February 2024 ↗

February 13, 2024

The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

February 13, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 10, 2024

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

3 Attractive Medical Stocks To Buy After Earnings ↗

February 08, 2024

Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare...

Via Talk Markets

Exelixis (EXEL) Q4 2023 Earnings Call Transcript ↗

February 06, 2024

EXEL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

February 06, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

February 01, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

January 25, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

January 23, 2024

From Exelixis, Inc.

Via Business Wire

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study ↗

January 23, 2024

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

Via InvestorPlace

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

January 22, 2024

From Bristol Myers Squibb

Via Business Wire

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

January 18, 2024

From Exelixis, Inc.

Via Business Wire

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com